Citations 2
Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancers (CA).
Matei, Daniela, Sachdev, Jasgit C. , Klein, Patrick , Burgess, Shelly, Clark, Romnee, Ramanathan, Ramesh K., Harb, Wael A., Matei, Daniela, Edelman, Martin J. , Rao, Satish B. , Morris, Elizabeth A.
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2551-2551
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Miller, David S. , Cloven, Noelle, Hendrickson, Andrea E. Wahner , DiSilvestro, Paul , Cristea, Mihaela , Berek, Jonathan S. , Chan, John K. , Clark, Romnee, Matulonis, Ursula A. , Monk, Bradley J. , Miller, David S , Moore, Kathleen N. , Secord, Angeles Alvarez , Geller, Melissa Ann , Fleming, Gini F. , Azodi, Masoud , Oza, Amit M. , Li, Yong
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5514-5514